GE HealthCare stock slips as StarGuide GX clearance and Wells Fargo outlook shape sentiment

Published on 09/10/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock trades near USD 64 on Nasdaq as of September 10, 2026, after losing about 3 percent following the StarGuide GX FDA filing on September 9, 2026. At the Wells Fargo conference on September 9, 2026, management highlighted 11 percent order growth and a USD 2.1 billion backlog.

Techniker bedient MRT-Scanner in hellem Krankenhaus-Untersuchungsraum mit Flurblick — GE HealthCare US36266G1076 zeigt einen modernen MRT-Scanner im hellen klinischen Krankenhaus mit Techniker, Illustration mit AI erstellt.

GE HealthCare Technologies Inc. stock (ISIN US36266G1076) is trading around USD 64.32 on Nasdaq on September 10, 2026, about 1.30 percent below the prior close as investors digest fresh product news and conference comments on growth and margins per data from MarketWatch at 10:00 a.m. EDT.

StarGuide GX filing and sector reaction

As Yahoo Finance reported on September 9, 2026, GE HealthCare announced that its StarGuide GX 4D SPECT/CT molecular imaging system is 510(k) pending with the U.S. Food and Drug Administration, a step that moves the scanner closer to full regulatory clearance in the United States.

According to Yahoo Finance, GE HealthCare stock fell about 3 percent at the close following the StarGuide GX announcement on September 9, 2026, underscoring that investors remain cautious despite the potential of next-generation molecular imaging to support theranostics and precision care.

Conference highlights: orders and backlog build

In parallel with the product news, management used the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026 to spell out a stronger order and backlog picture, which is shaping expectations for the second half of 2024. According to Investing.com on September 9, 2026, GE HealthCare reported 11 percent order growth on a trailing basis, a book-to-bill ratio of 1.15 and backlog growth to about USD 2.1 billion, with much of the increase driven by service contracts rather than one-off equipment deals.

Chief Executive Pete Arduini and Interim Chief Financial Officer George Newcomb said at the conference that roughly 80 percent of revenue entering the third quarter of 2024 was already committed, giving the company greater visibility on the near-term top line, according to Investing.com.

The backlog and committed revenue figures mark a clear improvement versus prior periods, with management indicating that trailing 12-month order growth is in the 5 percent range and reiterating a mid-single-digit organic growth ambition, as highlighted by Investing.com.

Margins, guidance and market perception

Margin dynamics also played a central role in the conference narrative. Management expects about 250 basis points of sequential margin improvement in the second half of 2024 compared with the first half, in line with the company’s typical seasonal pattern, according to Investing.com.

At the same time, GE HealthCare reaffirmed its medium-term operating margin target of 17 percent to 20 percent, positioning that range as a key profitability milestone that would be supported by higher service penetration and operational efficiencies, according to Investing.com.

Despite those margin ambitions, the stock’s recent performance suggests that the market is still demanding more evidence that the strategy will translate into sustained earnings growth. The shares have declined about 18 percent year to date and were cited as trading near USD 66.55 around the time of the conference, according to Investing.com, underscoring a disconnect between the improving backlog and a still cautious valuation multiple.

Latest earnings context and scanner portfolio expansion

The Wells Fargo remarks build on the company’s most recent quarterly report, which showed broad improvement across imaging and pharmaceutical diagnostics in the second quarter of 2024. According to Investing.com, orders in that second quarter rose 11 percent year on year, driven by both imaging equipment and associated service contracts.

At the same time, GE HealthCare’s book-to-bill ratio of 1.15 in the latest reported period indicates that orders are running ahead of revenue, a pattern that supports backlog expansion and future growth potential, as described by Investing.com.

The StarGuide GX filing is one of several recent moves to refresh the company’s advanced imaging portfolio. GE HealthCare previously secured CE Mark for its Photonova Spectra system in Europe, expanding international access to the technology, according to Zacks on September 9, 2026.

In addition, the company has unveiled three new systems in its Vivid cardiovascular ultrasound portfolio, named Vivid Explorer, Vivid Advanced and Vivid Focus, to support cardiac imaging and workflow across different care settings, according to Zacks. For investors, the expanding scanner portfolio underscores how GE HealthCare is trying to balance near-term margin headwinds with longer-term innovation-led growth.

Analyst views, valuation and risks

Analyst and investor sentiment around GE HealthCare remains mixed. According to MarketBeat on September 10, 2026, the company carries a consensus rating of Hold with an average price target of USD 77.73, suggesting upside of roughly 20 percent relative to the current USD 64 range but also indicating that many analysts prefer to wait for clearer execution on the margin and growth targets.

The same MarketBeat report highlights that institutional investors, including WINTON GROUP Ltd and several large asset managers, have built or expanded positions in GE HealthCare, reflecting confidence in the company’s long-term fundamentals despite short-term volatility.

On the risk side, GE HealthCare continues to face headwinds from tariffs, supply-chain challenges and a soft China market, factors that management explicitly acknowledged at the Wells Fargo conference, according to Investing.com. For investors, the key question is whether backlog growth and new product launches can offset these macro and cost pressures sufficiently to deliver the targeted 17 percent to 20 percent operating margin range.

Stock level, volatility and technical backdrop

Per MarketWatch’s Nasdaq quote, GE HealthCare stock was at USD 64.32 at 10:00 a.m. EDT on September 10, 2026, down USD 0.85 or 1.30 percent on the day, with an intraday trading range between USD 63.63 and USD 64.95 and a 52-week range from USD 58.75 to USD 89.77.

The current price places the shares about 9.5 percent above the 52-week low of USD 58.75 but roughly 28.4 percent below the 52-week high of USD 89.77, indicating that while some of the earlier drawdown has been retraced, the stock still trades well under its peak levels, according to the MarketWatch data.

Technical indicators underline a cautious near-term picture. A daily technical overview from Moneycontrol on September 10, 2026 shows GE HealthCare in a very bearish trend, with its 14-day relative strength index around 31, MACD at roughly -0.41 and several oscillators such as the stochastic and CCI in oversold territory, suggesting elevated volatility and an underperforming profile versus the broader market, according to Moneycontrol.